|
1
|
Welte K, Platzer E, Lu L, Gabrilove JL,
Levi E, Mertelsmann R and Moore MA: Purification and biochemical
characterization of human pluripotent hematopoietic
colony-stimulating factor. Proc Natl Acad Sci USA. 82:1526–1530.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nicola NA and Metcalf D: Binding of the
differentiation-inducer, granulocyte-colony-stimulating factor, to
responsive but not unresponsive leukemic cell lines. Proc Natl Acad
Sci USA. 81:3765–3769. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Demetri GD and Griffin JD: Granulocyte
colony-stimulating factor and its receptor. Blood. 78:2791–2808.
1991.PubMed/NCBI
|
|
4
|
Kawakami M, Tsutsumi H, Kumakawa T, Abe H,
Hirai M, Kurosawa S, et al: Levels of serum granulocyte
colony-stimulating factor in patients with infections. Blood.
76:1962–1964. 1990.PubMed/NCBI
|
|
5
|
Dale DC: Colony-stimulating factors for
the management of neutropenia in cancer patients. Drugs. 62(Suppl
1): 1–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carl W and Havens J: The cancer patient
with severe mucositis. Curr Rev Pain. 4:197–202. 2000. View Article : Google Scholar
|
|
7
|
Obermueller E, Vosseler S, Fusenig NE and
Mueller MM: Cooperative autocrine and paracrine functions of
granulocyte colony-stimulating factor and granulocyte-macrophage
colony-stimulating factor in the progression of skin carcinoma
cells. Cancer Res. 64:7801–7812. 2004. View Article : Google Scholar
|
|
8
|
Mueller MM, Peter W, Mappes M, Huelsen A,
Steinbauer H, Boukamp P, et al: Tumor progression of skin carcinoma
cells in vivo promoted by clonal selection, mutagenesis, and
autocrine growth regulation by granulocyte colony-stimulating
factor and granulocyte-macrophage colony-stimulating factor. Am J
Pathol. 159:1567–1579. 2001. View Article : Google Scholar
|
|
9
|
Braun B, Lange M, Oeckler R and Mueller
MM: Expression of G-CSF and GM-CSF in human meningiomas correlates
with increased tumor proliferation and vascularization. J
Neurooncol. 68:131–140. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix
MJ, Wu R, et al: Selection of invasive and metastatic
subpopulations from a human lung adenocarcinoma cell line. Am J
Respir Cell Mol Biol. 17:353–360. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Egberts JH, Cloosters V, Noack A,
Schniewind B, Thon L, Klose S, et al: Anti-tumor necrosis factor
therapy inhibits pancreatic tumor growth and metastasis. Cancer
Res. 68:1443–1450. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kulbe H, Thompson R, Wilson JL, Robinson
S, Hagemann T, Fatah R, et al: The inflammatory cytokine tumor
necrosis factor-α generates an autocrine tumor-promoting network in
epithelial ovarian cancer cells. Cancer Res. 67:585–592. 2007.
|
|
13
|
Stathopoulos GT, Kollintza A, Moschos C,
Psallidas I, Sherrill TP, Pitsinos EN, et al: Tumor necrosis
factor-α promotes malignant pleural effusion. Cancer Res.
67:9825–9834. 2007.
|
|
14
|
Koeffler HP, Gasson J, Ranyard J, Souza L,
Shepard M and Munker R: Recombinant human TNF alpha stimulates
production of granulocyte colony-stimulating factor. Blood.
70:55–59. 1987.PubMed/NCBI
|
|
15
|
Seger R, Ahn NG, Posada J, Munar ES,
Jensen AM, Cooper JA, et al: Purification and characterization of
mitogen-activated protein kinase activator(s) from epidermal growth
factor-stimulated A431 cells. J Biol Chem. 267:14373–14381.
1992.PubMed/NCBI
|
|
16
|
Hoshino R, Chatani Y, Yamori T, Tsuruo T,
Oka H, Yoshida O, et al: Constitutive activation of the 41-/43-kDa
mitogen-activated protein kinase signaling pathway in human tumors.
Oncogene. 18:813–822. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vantaggiato C, Formentini I, Bondanza A,
Bonini C, Naldini L and Brambilla R: ERK1 and ERK2
mitogen-activated protein kinases affect Ras-dependent cell
signaling differentially. J Biol. 5:142006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao Y, Li W, Wu J, Germann UA, Su MS,
Kuida K and Boucher DM: Extracellular signal-regulated kinase 2 is
necessary for mesoderm differentiation. Proc Natl Acad Sci USA.
100:12759–12764. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carlson SM, Chouinard CR, Labadorf A, Lam
CJ, Schmelzle K, Fraenkel E and White FM: Large-scale discovery of
ERK2 substrates identifies ERK-mediated transcriptional regulation
by ETV3. Sci Signal. 4:rs112011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou YY and Lu SC: Inhibition by rapamycin
of the lipoteichoic acid-induced granulocyte-colony stimulating
factor expression in mouse macrophages. Arch Biochem Biophys.
508:110–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou YY, Gao JI, Chang SF, Chang PY and Lu
SC: Rapamycin inhibits lipopolysaccharide induction of
granulocyte-colony stimulating factor and inducible nitric oxide
synthase expression in macrophages by reducing the levels of
octamer-binding factor-2. FEBS J. 278:85–96. 2011. View Article : Google Scholar
|
|
22
|
Armstrong DA, Phelps LN and Vincenti MP:
CCAAT enhancer binding protein-β regulates matrix
metalloproteinase-1 expression in interleukin-1β-stimulated A549
lung carcinoma cells. Mol Cancer Res. 7:1517–1524. 2009.
|
|
23
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karin M: Nuclear factor-κB in cancer
development and progression. Nature. 441:431–436. 2006.
|
|
25
|
Huber MA, Azoitei N, Baumann B, Grünert S,
Sommer A, Pehamberger H, et al: NF-κB is essential for
epithelial-mesenchymal transition and metastasis in a model of
breast cancer progression. J Clin Invest. 114:569–581. 2004.
|
